Reading Through Schering's Plowing

Got that? Read that one quickly and you'll come away with the impression of a company in control of its own destiny.

Look, by way of more favorable comparison, at the way Lisa Rapaport and Luke Timmerman at Bloomberg handle Hassan's overheated claim. Right after they quote him talking about control of destiny by "taking tough action now," we get a heading: "No Details."

In case you missed the point, the next sentence reads: "The cuts will concentrate on general and administrative spending, research and development, and manufacturing, Hassan said. He declined to provide details."

Instead of turning the article back to Hassan for a big finish about powering through difficulties, Bloomberg appropriately runs "Congressional Probe" as its last heading, tying it all together in the kicker by criticizing lack of data for the troubled drugs. Power that.

Know What You Own: Schering-Plough operates in the pharmaceutical industry, and some of the other stocks in its field include Bristol-Myers Squibb(BMY - Cramer's Take - Stockpickr), Pfizer(PFE - Cramer's Take - Stockpickr) and Sanofi-Aventis(SNY - Cramer's Take - Stockpickr). These stocks were recently trading at $22.00, +0.51%, $21.26, -0.37% and $38.38, -0.26%, respectively. For more on the value of knowing what you own, visit TheStreet.com's Investing A-to-Z section.